FCGR2A and cancer: The ability of mAbs to induce antibody-dependent cellular cytotoxicity (ADCC) via Fc: FcγR-interaction, as described in MIE5 and KE1e, is used to eliminate specific cells during cancer therapy, which can be accompanied by CRS as an adverse outcome.